公开(公告)号：US20210301020A1

公开(公告)日：2021-09-30

申请号：US17262339

申请日：2019-07-17

Applicant: AMGEN INC.

Inventor： Xin YU ,  Wenjun OUYANG ,  Chi-Ming Kevin LI ,  Jackson Graeme EGEN ,  Oh Kyu YOON ,  Ian Halsey DRIVER ,  Shunsuke TAKENAKA ,  Christy Ann THOMSON ,  Hongyu WANG

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.